Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
38
MGNX Quote, Financials, Valuation and Earnings
Last price:
$1.39
Seasonality move
:
7.11%
Day range:
$1.38 - $1.45
52-week range:
$0.99 - $3.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.69x
P/B ratio:
1.32x
Volume:
662.5K
Avg. volume:
1.2M
1-year change:
-58.82%
Market cap:
$88.6M
Revenue:
$150M
EPS (TTM):
-$1.21
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MGNX
MacroGenics, Inc.
|
$25.6M | -$0.51 | 43.69% | -91.88% | $3.40 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.56% | 310.03% | $325.88 |
|
GILD
Gilead Sciences, Inc.
|
$7.5B | $2.14 | 1.2% | 33.03% | $131.80 |
|
MRK
Merck & Co., Inc.
|
$17B | $2.35 | 5.82% | 39.12% | $107.46 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -1.96% | 736.93% | $28.91 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -0.81% | 32.75% | $782.90 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MGNX
MacroGenics, Inc.
|
$1.40 | $3.40 | $88.6M | -- | $0.00 | 0% | 0.69x |
|
AMGN
Amgen, Inc.
|
$317.74 | $325.88 | $171.1B | 24.56x | $2.38 | 3% | 4.79x |
|
GILD
Gilead Sciences, Inc.
|
$120.40 | $131.80 | $149.4B | 18.65x | $0.79 | 2.61% | 5.21x |
|
MRK
Merck & Co., Inc.
|
$100.30 | $107.46 | $248.9B | 13.27x | $0.85 | 3.23% | 3.96x |
|
PFE
Pfizer Inc.
|
$25.85 | $28.91 | $147B | 15.07x | $0.43 | 6.65% | 2.35x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$741.29 | $782.90 | $77.9B | 17.75x | $0.88 | 0.48% | 5.73x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MGNX
MacroGenics, Inc.
|
61.55% | 1.724 | 100.93% | 4.85x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.025 | 20.79% | 1.06x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MGNX
MacroGenics, Inc.
|
$59.5M | $18.6M | -50.41% | -88.47% | 25.59% | -$30.6M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
MacroGenics, Inc. vs. Competitors
-
Which has Higher Returns MGNX or AMGN?
Amgen, Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 33.55%. MacroGenics, Inc.'s return on equity of -88.47% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital MGNXMacroGenics, Inc.81.63% $0.27 $174.3M AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About MGNX or AMGN?
MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 142.86%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could grow by 2.56%. Given that MacroGenics, Inc. has higher upside potential than Amgen, Inc., analysts believe MacroGenics, Inc. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MGNXMacroGenics, Inc.1 5 0 AMGNAmgen, Inc.10 15 2 -
Is MGNX or AMGN More Risky?
MacroGenics, Inc. has a beta of 1.516, which suggesting that the stock is 51.583% more volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock MGNX or AMGN?
MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 3% to investors and pays a quarterly dividend of $2.38 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.
-
Which has Better Financial Ratios MGNX or AMGN?
MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. MacroGenics, Inc.'s net income of $16.8M is lower than Amgen, Inc.'s net income of $3.2B. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 24.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.69x versus 4.79x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MGNXMacroGenics, Inc.0.69x -- $72.8M $16.8M AMGNAmgen, Inc.4.79x 24.56x $9.6B $3.2B
-
Which has Higher Returns MGNX or GILD?
Gilead Sciences, Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 39.21%. MacroGenics, Inc.'s return on equity of -88.47% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital MGNXMacroGenics, Inc.81.63% $0.27 $174.3M GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About MGNX or GILD?
MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 142.86%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $131.80 which suggests that it could grow by 9.47%. Given that MacroGenics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe MacroGenics, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MGNXMacroGenics, Inc.1 5 0 GILDGilead Sciences, Inc.16 8 0 -
Is MGNX or GILD More Risky?
MacroGenics, Inc. has a beta of 1.516, which suggesting that the stock is 51.583% more volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock MGNX or GILD?
MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.61% to investors and pays a quarterly dividend of $0.79 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios MGNX or GILD?
MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. MacroGenics, Inc.'s net income of $16.8M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 18.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.69x versus 5.21x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MGNXMacroGenics, Inc.0.69x -- $72.8M $16.8M GILDGilead Sciences, Inc.5.21x 18.65x $7.8B $3.1B
-
Which has Higher Returns MGNX or MRK?
Merck & Co., Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 33.68%. MacroGenics, Inc.'s return on equity of -88.47% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital MGNXMacroGenics, Inc.81.63% $0.27 $174.3M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About MGNX or MRK?
MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 142.86%. On the other hand Merck & Co., Inc. has an analysts' consensus of $107.46 which suggests that it could grow by 7.14%. Given that MacroGenics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe MacroGenics, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings MGNXMacroGenics, Inc.1 5 0 MRKMerck & Co., Inc.14 13 0 -
Is MGNX or MRK More Risky?
MacroGenics, Inc. has a beta of 1.516, which suggesting that the stock is 51.583% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.
-
Which is a Better Dividend Stock MGNX or MRK?
MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.23% to investors and pays a quarterly dividend of $0.85 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MGNX or MRK?
MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. MacroGenics, Inc.'s net income of $16.8M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.69x versus 3.96x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MGNXMacroGenics, Inc.0.69x -- $72.8M $16.8M MRKMerck & Co., Inc.3.96x 13.27x $17.2B $5.8B
-
Which has Higher Returns MGNX or PFE?
Pfizer Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 21.32%. MacroGenics, Inc.'s return on equity of -88.47% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital MGNXMacroGenics, Inc.81.63% $0.27 $174.3M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About MGNX or PFE?
MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 142.86%. On the other hand Pfizer Inc. has an analysts' consensus of $28.91 which suggests that it could grow by 11.86%. Given that MacroGenics, Inc. has higher upside potential than Pfizer Inc., analysts believe MacroGenics, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings MGNXMacroGenics, Inc.1 5 0 PFEPfizer Inc.7 15 1 -
Is MGNX or PFE More Risky?
MacroGenics, Inc. has a beta of 1.516, which suggesting that the stock is 51.583% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock MGNX or PFE?
MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.65% to investors and pays a quarterly dividend of $0.43 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios MGNX or PFE?
MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. MacroGenics, Inc.'s net income of $16.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.69x versus 2.35x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MGNXMacroGenics, Inc.0.69x -- $72.8M $16.8M PFEPfizer Inc.2.35x 15.07x $16.7B $3.6B
-
Which has Higher Returns MGNX or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 38.89%. MacroGenics, Inc.'s return on equity of -88.47% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital MGNXMacroGenics, Inc.81.63% $0.27 $174.3M REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About MGNX or REGN?
MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 142.86%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $782.90 which suggests that it could grow by 5.61%. Given that MacroGenics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe MacroGenics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MGNXMacroGenics, Inc.1 5 0 REGNRegeneron Pharmaceuticals, Inc.14 8 0 -
Is MGNX or REGN More Risky?
MacroGenics, Inc. has a beta of 1.516, which suggesting that the stock is 51.583% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock MGNX or REGN?
MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MGNX or REGN?
MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. MacroGenics, Inc.'s net income of $16.8M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.69x versus 5.73x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MGNXMacroGenics, Inc.0.69x -- $72.8M $16.8M REGNRegeneron Pharmaceuticals, Inc.5.73x 17.75x $3.8B $1.5B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 4.13% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 2.57% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 4.39% over the past day.
